Engineered antibodies: A new tool for use in diabetes research

Diabetes Research and Clinical Practice

Volumn 74, Issue 2 SUPPL., 2006, Pages

  Padoa, Carolyn J ^a   Crowther, Nigel J ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Autoantibodies; Fab; Insulin; scFv; Type 1 diabetes

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; BASILIXIMAB; BEVACIZUMAB; CETUXIMAB; DACLIZUMAB; EFALIZUMAB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; INFLIXIMAB; INSULIN; OMALIZUMAB; RECOMBINANT ANTIBODY; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; ASTHMA; BREAST CANCER; COLORECTAL CANCER; CROHN DISEASE; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; GENE REARRANGEMENT; GENETIC ENGINEERING; HUMAN; HYBRIDOMA; MEDICAL RESEARCH; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHODGKIN LYMPHOMA; NONHUMAN; PHAGE DISPLAY; PSORIASIS; RHEUMATOID ARTHRITIS; RIBOSOME; TECHNOLOGY;

EID: 33749235293     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2006.06.033     Document Type: Article

References (96)

1. von Behring E., and Kitasato S. The mechanism of diphtheria immunity and tetanus immunity in animals. Mol. Immunol. 28 12 (1890) 1319-1320 1317
2. Edelman G.M., and Benacerraf B. On structural and functional relations between antibodies and proteins of the gamma-system. Proc. Natl. Acad. Sci. U.S.A. 48 (1962) 1035-1042
3. Kehry M., Sibley C., Fuhrman J., et al. Amino acid sequence of a mouse immunoglobulin μ chain. Proc. Natl. Acad. Sci. U.S.A. 76 6 (1979) 2932-2936
4. Wu T.T., and Kabat E.A. An analysis of the sequences of the variable regions of Bence-Jones proteins and myeloma light chains and their implication for antibody complementarity. J. Exp. Med. 132 (1970) 211-249
5. Kabat E.A., and Wu T.T. Attempts to locate complementarity-determining residues in the variable positions of light and heavy chains. Ann. NY Acad. Sci. 190 (1971) 382-393
6. Milstein C. General motors cancer research foundation awards: monoclonal antibodies. Cancer 49 10 (1982) 1953-1957
7. Azzazy H.M.E., and Highsmith Jr. W.E. Phage display technology: clinical applications and recent innovations. Clin. Biochem. 35 (2002) 425-445
8. Weigert M., Gatmaitan L., Loh E., et al. Rearrangement of genetic information may produce immunoglobulin diversity. Nature 276 5690 (1978) 785-790
9. Cory S., Tyler B.M., and Adams J.M. Sets of immunoglobulin V kappa genes homologous to ten cloned V kappa sequences: implications for the number of germline V kappa genes. J. Mol. Appl. Genet. 1 2 (1981) 103-116
10. Fitzsimmons S.P., Rotz B.T., and Shapiro M.A. Asymmetric contribution to Ig repertoire diversity by V kappa exons: differences in the utilization of V kappa 10 exons. J. Immunol. 161 5 (1998) 2290-2300
11. Brack C., Hirama M., Lenhard-Schuller R., and Tonegawa S. Complete immunoglobulin gene is created by somatic recombination. Cell 15 (1978) 1-14
12. Davis M.M., Calame K., Early P.W., et al. An immunoglobulin heavy-chain gene is formed by at least two recombinational events. Nature 283 5749 (1980) 733-739
13. Köhler G., and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 5517 (1975) 495-497
14. Vaughan T.J., Williams A.J., Pritchard K., et al. Human antibodies with sub-nanomolar affinities isolated from a large non-immunised phage display library. Nat. Biotechnol. 14 3 (1996) 309-314
15. Winter G., and Milstein C. Man-made antibodies. Nature 349 6307 (1991) 293-299
16. Morrison S.L., Johnson M.J., Herzenberg L.A., and Oi V.T. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. U.S.A. 81 21 (1984) 6851-6855
17. Adair J.R. Engineering antibodies for therapy. Immunol. Rev. 130 (1992) 5-40
18. Jones P.T., Dear P.H., Foote J., et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321 6069 (1986) 522-525
19. Verhoeyen M., Milstein C., and Winter G. Reshaping human antibodies: grafting an antilysozyme activity. Science 239 4847 (1988) 1534-1536
20. Kashmiri S.V., de Pascalis R., Gonzales N.R., and Schlom J. SDR grafting-a new approach to antibody humanization. Methods 36 1 (2005) 25-34
21. Huston J.S., Levinson D., Mudgett-Hunter M., et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 5879-5883
22. Riechmann L., and Muyldermans S. Single domain antibodies: comparison of camel VH and camelised human VH domains. J. Immunol. Meth. 231 (1999) 25-38
23. Padoa C.J., Banga J.P., Madec A.M., et al. Recombinant Fabs of human monoclonal antibodies specific to the middle epitope of GAD65 inhibit type 1 diabetes-specific GAD65Abs. Diabetes 52 11 (2003) 2689-2695
24. Padoa C.J., Crowther N.J., Thomas J.W., et al. Epitope analysis of insulin autoantibodies using recombinant Fab. Clin. Exp. Immunol. 140 3 (2005) 564-571
25. Schlosser M., Banga J.P., Madec A.M., et al. Dynamic changes of GAD65 autoantibody epitope specificities in individuals at risk of developing type 1 diabetes. Diabetologia 48 5 (2005) 922-930
26. Glockshuber R., Malia M., Pfitzinger I., and Plückthun A. A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry 29 6 (1990) 1362-1367
27. Bird R.E., Hardman K.D., Jacobson J.W., et al. Single-chain antigen-binding proteins. Science 243 (1988) 423-426
28. Anand N.N., Dubuc G., Phipps J., et al. Synthesis and expression in Escherichia coli of cistronic DNA encoding an antibody fragment specific for a Salmonella serotype B O-antigen. Gene 100 (1991) 39-44
29. Takkinen K., Laukkanen M.L., Sizmann D., et al. An active single-chain antibody containing a cellulase linker domain is secreted by Escherichia coli. Protein Eng. 4 7 (1991) 837-841
30. Denzin L.K., and Voss Jr. E.W. Construction, characterization, and mutagenesis of an anti-fluorescein single chain antibody idiotype family. J. Biol. Chem. 267 13 (1992) 8925-8931
31. Malby R.L., Caldwell J.B., Gruen L.C., et al. Recombinant antineuraminidase single chain antibody: expression, characterization, and crystallization in complex with antigen. Proteins 16 1 (1993) 57-63
32. Lilley G.G., Dolezal O., Hillyard C.J., Bernard C., and Hudson P.J. Recombinant single-chain antibody peptide conjugates expressed in Escherichia coli for the rapid diagnosis of HIV. J. Immunol. Meth. 171 2 (1994) 211-226
33. Smith G.P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228 4705 (1985) 1315-1317
34. Pack P., and Plückthun A. Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli. Biochemistry 31 6 (1992) 1579-1584
35. Müller K.M., Arndt K.M., Strittmatter W., and Plückthun A. The first constant domain (C(H)1 and C(L)) of an antibody used as heterodimerization domain for bispecific miniantibodies. FEBS Lett. 422 2 (1998) 259-264
36. H3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 56 13 (1996) 3055-3061
37. Adams G.P., McCartney J.E., Tai M.S., et al. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res. 53 17 (1993) 4026-4034
38. Holliger P., Prospero T., and Winter G. Diabodies: small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. U.S.A. 90 14 (1993) 6444-6448
39. Iliades P., Kortt A.A., and Hudson P.J. Triabodies: single chain Fv fragments without a linker form trivalent trimers. FEBS Lett. 409 3 (1997) 437-441
40. McCafferty J., Griffiths A.D., Winter G., and Chiswell D.J. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348 6301 (1990) 552-554
41. Parmley S.F., and Smith G.P. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene 73 2 (1988) 305-318
42. Hawkins R.E., and Winter G. Cell selection strategies for making antibodies from variable gene libraries: trapping the memory pool. Eur. J. Immunol. 22 (1992) 867-870
43. Persson M.A., Caothien R.H., and Burton D.R. Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 2432-2436
44. Hayashi N., Welschof M., Zewe M., et al. Simultaneous mutagenesis of antibody CDR regions by overlap extension and PCR. Biotechniques 17 2 (1994) 314-315 310, 312
45. Pini A., Viti F., Santucci A., et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J. Biol. Chem. 273 34 (1998) 21769-21776
46. de Carvalho Nicacio C., Williamson R.A., Parren P.W., et al. Neutralizing human Fab fragments against measles virus recovered by phage display. J. Virol. 76 1 (2002) 251-258
47. Larrick J.W., Danielsson L., Brenner C.A., et al. Rapid cloning of rearranged immunoglobulin genes from human hybridoma cells using mixed primers and the polymerase chain reaction. Biochem. Biophys. Res. Commun. 160 3 (1989) 1250-1256
48. Zebedee S.L., Barbas III C.F., Hom Y.L., et al. Human combinatorial antibody libraries to hepatitis B surface antigen. Proc. Natl. Acad. Sci. U.S.A. 89 8 (1992) 3175-3179
49. Sheets M.D., Amersdorfer P., Finnern R., et al. Efficient construction of a large nonimmune phage antibody library: the production of high affinity human single-chain antibodies to protein antigens. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 6157-6162
50. Kang A.S., Barbas C.F., Janda K.D., et al. Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces. Proc. Natl. Acad. Sci. U.S.A. 88 10 (1991) 4363-4366
51. Barbas III C.F., Kang A.S., Lerner R.A., and Benkovic S.J. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc. Natl. Acad. Sci. U.S.A. 88 18 (1991) 7978-7982
52. Skerra A., Dreher M.L., and Winter G. Filter screening of antibody Fab fragments secreted from individual bacterial colonies: specific detection of antigen binding with a two-membrane system. Anal. Biochem. 196 1 (1991) 151-155
53. Griffiths A.D., Williams S.C., Hartley O., et al. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 13 14 (1994) 3245-3260
54. Watkins J.D., Beuerlein G., Wu H., et al. Discovery of human antibodies to cell surface antigens by capture lift screening of phage-expressed antibody libraries. Anal. Biochem. 256 2 (1998) 169-177
55. Schier R., and Marks J.D. Efficient in vitro affinity maturation of phage antibodies using BIAcore guided selections. Hum Antibodies Hybridomas 7 3 (1996) 97-105
56. Hanes J., and Plückthun A. In vitro selection, and evolution of functional proteins by using ribosome display. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 4937-4942
57. Schaffitzel C., Hanes J., Jermutus L., and Plückthun A. Ribosome display: an in vitro method for selection and evolution of antibodies from libraries. J. Immunol. Meth. 231 (1999) 119-135
58. Bruggemann M., Spicer C., Buluwela L., et al. Human antibody production in transgenic mice: expression from 100 kb of the human IgH locus. Eur. J. Immunol. 21 5 (1991) 1323-1326
59. Bruggemann M., and Taussig M.J. Production of human antibody repertoires in transgenic mice. Curr. Opin. Biotechnol. 8 4 (1997) 455-458
60. Duchosal M.A., Eming S.A., Mcconahey P.J., and Dixon F.J. The hu-PBL-SCID mouse model. Long-term human serologic evolution associated with the xenogeneic transfer of human peripheral blood leukocytes into SCID mice. Cell. Immunol. 139 2 (1992) 468-477
61. Yokota T., Milenic D.E., Whitlow M., and Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 52 12 (1992) 3402-3408
62. Yamaguchi A., Ding K., Maehara M., et al. Expression of nm23-H1 Gene and Sialyl Lewis X antigen in breast cancer. Oncology 55 (1998) 357-362
63. Raju R., Foote J., Banga J.P., et al. Analysis of GAD65 autoantibodies in Stiff-Person syndrome patients. J. Immunol. 175 11 (2005) 7755-7762
64. Vandewalle C.L., Falorni A., Svanholm S., et al. High diagnostic sensitivity of glutamate decarboxylase autoantibodies in insulin-dependent diabetes mellitus with clinical onset between age 20 and 40 years. The Belgian Diabetes Registry. J. Clin. Endocrinol. Metab. 80 3 (1995) 846-851
65. Jaume J.C., Parry S.L., Madec A.M., et al. Suppressive effect of glutamic acid decarboxylase 65-specific autoimmune B lymphocytes on processing of T cell determinants located within the antibody epitope. J. Immunol. 169 2 (2002) 665-672
66. Reijonen H., Daniels T.L., Lernmark A., and Nepom G.T. GAD65-specific autoantibodies enhance the presentation of an immunodominant T-cell epitope from GAD65. Diabetes 49 10 (2000) 1621-1626
67. Tuomi T., Rowley M.J., Knowles W.J., et al. Autoantigenic properties of native and denatured glutamic acid decarboxylase: evidence for a conformational epitope. Clin. Immunol. Immunopathol. 71 1 (1994) 53-59
68. Schwartz H.L., Chandonia J.M., Kash S.F., et al. High-resolution autoreactive epitope mapping and structural modeling of the 65 kDa form of human glutamic acid decarboxylase. J. Mol. Biol. 287 5 (1999) 983-999
69. Daw K., and Powers A.C. Two distinct glutamic acid decarboxylase auto-antibody specificities in IDDM target difference epitopes. Diabetes 44 2 (1995) 216-220
70. Hampe C.S., Hammerle L.P., Bekris L., et al. Recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different GAD antibody-positive phenotypes. J. Clin. Endocrinol. Metab. 85 12 (2000) 4671-4679
71. Björk E., Velloso L.A., Kämpe O., and Karlsson F.A. GAD autoantibodies in IDDM, Stiff-Man Syndrome, and autoimmune polyendocrine syndrome type I recognize different epitopes. Diabetes 43 (1994) 161-165
72. Daw K., Ujihara N., Atkinson M., and Powers A.C. Glutamic acid decarboxylase autoantibodies in Stiff-Man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. J. Immunol. 156 2 (1996) 818-825
73. Ziegler B., Schlosser M., Luhder F., et al. Murine monoclonal glutamic acid decarboxylase (GAD)65 antibodies recognize autoimmune-associated GAD epitope regions targeted in patients with type 1 diabetes mellitus and Stiff-Man syndrome. Acta Diabetol. 33 3 (1996) 225-231
74. Falorni A., Gambelunghe G., Forini F., et al. Autoantibody recognition of COOH-terminal epitopes of GAD65 marks the risk for insulin requirement in adult-onset diabetes mellitus. J. Clin. Endocrinol. Metab. 85 1 (2000) 309-316
75. Bonifacio E., Lampasona V., Bernasoni L., and Ziegler A.G. Maturation of the humoral autoimmune response to epitopes of GAD in preclinical childhood type 1 diabetes. Diabetes 49 2 (2000) 202-208
76. Simitsek P.D., Campbell D.G., Lanzavecchia A., et al. Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants. J. Exp. Med. 181 6 (1995) 1957-1963
77. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu. Rev. Immunol. 15 (1997) 821-850
78. Ziegler A.G., Hummel M., Schenker M., and Bonifacio E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 48 (1999) 460-468
79. Graham J., Hagopian W.A., Kockum I., et al. Genetic effects on age-dependent onset and islet cell autoantibody markers in type 1 diabetes. Diabetes 51 5 (2002) 1346-1355
80. Karjalainen J., Salmela P., Ilonen J., et al. A comparison of childhood and adult type I diabetes mellitus. N. Engl. J. Med. 320 14 (1989) 881-886
81. Diaz J.L., and Wilkin T. Differences in epitope restriction of autoantibodies to native human insulin (IAA) and antibodies to heterologous insulin (IA). Diabetes 36 1 (1987) 66-72
82. Wilkin T., Mirza I., Armitage M., et al. Insulin autoantibody polymorphisms with greater discrimination for diabetes in humans. Diabetologia 31 (1988) 670-674
83. Devendra D., Galloway T.S., Horton S.J., et al. The use of phage display to distinguish insulin autoantibody (IAA) from insulin antibody (IA) idiotypes. Diabetologia 46 (2003) 802-809
84. Schlosser M., Hahmann J., Ziegler B., et al. Sensitive monoclonal antibody-based sandwich ELISA for determination of the diabetes-associated autoantigen glutamic acid decarboxylase GAD65. J. Immunoassay 18 (1997) 289-307
85. Kolm-Litty V., Berlo S., Bonifacio E., et al. Human monoclonal antibodies isolated from type I diabetes patients define multiple epitopes in the protein tyrosine phosphatase-like IA-2 antigen. J. Immunol. 165 (2000) 4676-4684
86. Daniel D., and Wegmann D.R. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 956-960
87. King H., Aubert R.E., and Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diab. Care 21 9 (1998) 1414-1431
88. Wareham N.J., Byrne C.D., Williams R., et al. Fasting proinsulin concentrations predict the development of type 2 diabetes. Diab. Care 22 2 (1999) 262-270
89. Sobey W.J., Beer S.F., Carrington C.A., et al. Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split proinsulin and 32-33 split proinsulins. Biochem. J. 260 (1989) 535-541
90. Warren D.J., Bjerner J., Paus E., et al. Use of an in vivo biotinylated single-chain antibody as capture reagent in an immunometric assay to decrease the incidence of interference from heterophilic antibodies. Clin. Chem. 51 5 (2005) 830-838
91. Yalow R.S., and Berson S.A. Plasma insulin concentrations in nondiabetic and early diabetic subjects. Determinations by a new sensitive immuno-assay technic. Diabetes 9 4 (1959) 254-260
92. Kim S.J., Park Y., and Hong H.J. Antibody engineering for the development of therapeutic antibodies. Mol. Cells 20 1 (2005) 17-29
93. Marks J.D., Hoogenboom H.R., Griffiths A.D., and Winter G. Molecular evolution of proteins on filamentous phage. J. Biol. Chem. 267 23 (1992) 16007-16010
94. Hudson P.J., and Souriau C. Engineered antibodies. Nature Med. 9 1 (2003) 129-134
95. Binder K.A., Banga J.P., Madec A.M., et al. Epitope analysis of GAD65Ab using fusion proteins and rFab. J. Immunol. Meth. 295 (2004) 101-109
96. Nijpels G., Popp-Snijders C., Kostense P.J., et al. Fasting proinsulin and 2-h post-load glucose levels predict the conversion to NIDDM in subjects with impaired glucose tolerance: the Hoorn Study. Diabetologia 39 1 (1996) 113-118